A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Bempedoic acid (Primary) ; Ezetimibe (Primary)
  • Indications Atherosclerosis; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms CLEAR Tranquility
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 02 Oct 2017 According to an Esperion Therapeutics media release, top-line results are expected to be announced by the second quarter of 2018.
    • 02 Oct 2017 According to an Esperion Therapeutics media release, status changed from recruiting to active, no longer recruiting.
    • 04 May 2017 According to an Esperion Therapeutics media release, the patient enrollment in this study will be completed in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top